Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of Miricorilant in Healthy Men
NCT03878264Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of miricorilant in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Corcept Therapeutics. Primary endpoints: Absolute Oral Bioavailability (F) of CORT118335 at Day 12, Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT118335 at Day 17 and 2 more. Started Aug 2018; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03878264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878264.